Viking Therapeutics, Inc. has announced encouraging preliminary results from the Phase 2 clinical trial for VK2735. This announcement has led to a surge of over 81% in the value of Viking shares in pre-market trading.
VK2735 is a pioneering dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. This treatment has been primarily developed to target metabolic disorders, such as obesity.
The results from the Phase 2 Venture trial have demonstrated their primary and secondary objectives. These include significant body weight reduction in patients taking VK2735, in comparison to those on the placebo.
Patients who received weekly doses of VK2735 reported a reduction as high as 14.7% in their mean body weight within a span of 13 weeks.
Following these positive results, Viking Therapeutics intends to coordinate with the FDA to determine the future course of action for the development of VK2735.
In the pre-market activity on the Nasdaq, Viking Therapeutics' shares showcased a robust increase of 81.91%, trading at $70.00.
